Cargando…

Clinical epidemiology and disease burden of nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic fat accumulation after the exclusion of other causes of hepatic steatosis, including other causes of liver disease, excessive alcohol consumption, and other conditions that may lead to hepatic steatosis. NAFLD encompasses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perumpail, Brandon J, Khan, Muhammad Ali, Yoo, Eric R, Cholankeril, George, Kim, Donghee, Ahmed, Aijaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743497/ https://www.ncbi.nlm.nih.gov/pubmed/29307986 http://dx.doi.org/10.3748/wjg.v23.i47.8263

Ejemplares similares

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
por: Iqbal, Umair, et al.
Publicado: (2019)

An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease
por: Perumpail, Brandon J., et al.
Publicado: (2017)

Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
por: Dibba, Pratima, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft
por: Liu, Andy, et al.
Publicado: (2018)

Recent Epidemiology of Nonalcoholic Fatty Liver Disease
por: Murag, Soumya, et al.
Publicado: (2021)

Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary
por: Dibba, Pratima, et al.
Publicado: (2019)

Types of Physical Activity in Nonalcoholic Fatty Liver Disease and All-Cause and Cardiovascular Mortality
por: Kim, Donghee, et al.
Publicado: (2023)

Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease
por: Cholankeril, George, et al.
Publicado: (2017)

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
por: Li, Andrew A., et al.
Publicado: (2020)

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
por: Wijarnpreecha, Karn, et al.
Publicado: (2021)

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
por: Konyn, Peter, et al.
Publicado: (2023)

Body fat distribution: a crucial target for intervention in nonalcoholic fatty liver disease and fibrosis
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents
por: Cholankeril, George, et al.
Publicado: (2017)

The importance of a multidisciplinary approach to hepatocellular carcinoma
por: Siddique, Osama, et al.
Publicado: (2017)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

When to Initiate Weight Loss Medications in the NAFLD Population
por: Yoo, Eric R., et al.
Publicado: (2018)

Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States
por: Kim, Donghee, et al.
Publicado: (2017)

Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic
por: Kim, Donghee, et al.
Publicado: (2021)

Association between cagA negative Helicobacter pylori status and nonalcoholic fatty liver disease among adults in the United States
por: Kang, Seung Joo, et al.
Publicado: (2018)

Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States
por: Kim, Donghee, et al.
Publicado: (2022)

Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals
por: Yoo, Eric R., et al.
Publicado: (2017)

Nutritional Needs and Support for Children with Chronic Liver Disease
por: Yang, Christine H., et al.
Publicado: (2017)

Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis
por: Perumpail, Brandon J., et al.
Publicado: (2017)

Judicious Use of Lipid Lowering Agents in the Management of NAFLD
por: Iqbal, Umair, et al.
Publicado: (2018)

Anti-Diabetic Medications for the Pharmacologic Management of NAFLD
por: Cholankeril, Rosann, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks
por: Cheung, Amanda, et al.
Publicado: (2021)

Hepatic encephalopathy: what the multidisciplinary team can do
por: Liu, Andy, et al.
Publicado: (2017)

Case Report of Isoniazid-Related Acute Liver Failure Requiring Liver Transplantation
por: Li, Andrew A., et al.
Publicado: (2018)

Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience
por: Aggarwal, Avin, et al.
Publicado: (2017)

The Role of Vitamin E in the Treatment of NAFLD
por: Perumpail, Brandon J., et al.
Publicado: (2018)

The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD
por: Perumpail, Brandon J., et al.
Publicado: (2019)

Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD
por: Perumpail, Brandon J., et al.
Publicado: (2018)

Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States
por: Kim, Donghee, et al.
Publicado: (2023)

Recent advances in liver transplantation with HCV seropositive donors
por: Murag, Soumya, et al.
Publicado: (2019)

Nonalcoholic fatty liver disease burden: Australia, 2019–2030
por: Adams, Leon A, et al.
Publicado: (2020)

Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD
por: Dibba, Pratima, et al.
Publicado: (2018)

Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
por: Akhtar, Daud H., et al.
Publicado: (2019)

The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the Elderly in the Asia-Pacific Region: An Insight from the Global Burden of Disease Study 2019
por: Danpanichkul, Pojsakorn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ljpl9nn1n4o0679h3j324g6l45